WO2007066737A1 - 核酸の複製の方法及び新規人工塩基対 - Google Patents
核酸の複製の方法及び新規人工塩基対 Download PDFInfo
- Publication number
- WO2007066737A1 WO2007066737A1 PCT/JP2006/324484 JP2006324484W WO2007066737A1 WO 2007066737 A1 WO2007066737 A1 WO 2007066737A1 JP 2006324484 W JP2006324484 W JP 2006324484W WO 2007066737 A1 WO2007066737 A1 WO 2007066737A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- group
- acid
- added
- hydrogen
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 54
- 230000010076 replication Effects 0.000 title claims abstract description 40
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 30
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 21
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 21
- 238000006243 chemical reaction Methods 0.000 claims abstract description 43
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 18
- 239000002253 acid Substances 0.000 claims description 88
- 229910052739 hydrogen Inorganic materials 0.000 claims description 42
- 239000001257 hydrogen Substances 0.000 claims description 42
- 150000001875 compounds Chemical class 0.000 claims description 41
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 38
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 36
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 35
- 238000013518 transcription Methods 0.000 claims description 32
- 230000035897 transcription Effects 0.000 claims description 32
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 28
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 229960002685 biotin Drugs 0.000 claims description 14
- 235000020958 biotin Nutrition 0.000 claims description 14
- 239000011616 biotin Substances 0.000 claims description 14
- 238000010839 reverse transcription Methods 0.000 claims description 13
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 230000000692 anti-sense effect Effects 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 239000000049 pigment Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- UKUVVAMSXXBMRX-UHFFFAOYSA-N 2,4,5-trithia-1,3-diarsabicyclo[1.1.1]pentane Chemical compound S1[As]2S[As]1S2 UKUVVAMSXXBMRX-UHFFFAOYSA-N 0.000 claims 1
- 241000209761 Avena Species 0.000 claims 1
- 235000007319 Avena orientalis Nutrition 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 235000013339 cereals Nutrition 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 abstract description 2
- 229910019142 PO4 Inorganic materials 0.000 abstract 2
- 239000010452 phosphate Substances 0.000 abstract 2
- ZSKGQVFRTSEPJT-UHFFFAOYSA-N pyrrole-2-carboxaldehyde Chemical compound O=CC1=CC=CN1 ZSKGQVFRTSEPJT-UHFFFAOYSA-N 0.000 abstract 2
- WIPHNVWGXOHNEF-UHFFFAOYSA-N 7-thiophen-2-yl-1h-imidazo[4,5-b]pyridine Chemical compound C1=CSC(C=2C=3N=CNC=3N=CC=2)=C1 WIPHNVWGXOHNEF-UHFFFAOYSA-N 0.000 abstract 1
- 239000005549 deoxyribonucleoside Substances 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 abstract 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 93
- 238000001228 spectrum Methods 0.000 description 89
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 44
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 41
- 239000000047 product Substances 0.000 description 39
- 239000000203 mixture Substances 0.000 description 38
- 229910052774 Proactinium Inorganic materials 0.000 description 33
- 239000004020 conductor Substances 0.000 description 31
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 26
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 24
- 239000007788 liquid Substances 0.000 description 19
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 18
- 150000002500 ions Chemical class 0.000 description 18
- 229910052698 phosphorus Inorganic materials 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 239000000344 soap Substances 0.000 description 14
- 239000011734 sodium Substances 0.000 description 13
- 241000270322 Lepidosauria Species 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- 238000007792 addition Methods 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 238000001035 drying Methods 0.000 description 10
- 229910052705 radium Inorganic materials 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000283715 Damaliscus lunatus Species 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000005755 formation reaction Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical compound CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- ZOOODBUHSVUZEM-UHFFFAOYSA-N ethoxymethanedithioic acid Chemical compound CCOC(S)=S ZOOODBUHSVUZEM-UHFFFAOYSA-N 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- 244000061458 Solanum melongena Species 0.000 description 5
- 235000002597 Solanum melongena Nutrition 0.000 description 5
- 241001080137 Tosta Species 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000012991 xanthate Substances 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 229920008712 Copo Polymers 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000000976 ink Substances 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000013076 target substance Substances 0.000 description 3
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000282575 Gorilla Species 0.000 description 2
- 101100489867 Mus musculus Got2 gene Proteins 0.000 description 2
- 240000001090 Papaver somniferum Species 0.000 description 2
- 235000008753 Papaver somniferum Nutrition 0.000 description 2
- 235000012012 Paullinia yoco Nutrition 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 241000534944 Thia Species 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 108010027090 biotin-streptavidin complex Proteins 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 2
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 2
- 101150008563 spir gene Proteins 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 description 2
- MWDNZMWVENFVHT-UHFFFAOYSA-L (2-decoxy-2-oxoethyl)-[2-[2-[(2-decoxy-2-oxoethyl)-dimethylazaniumyl]ethylsulfanyl]ethyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCOC(=O)C[N+](C)(C)CCSCC[N+](C)(C)CC(=O)OCCCCCCCCCC MWDNZMWVENFVHT-UHFFFAOYSA-L 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- SMNJTHDCJZUGHR-KJWHEZOQSA-N (4R,8R,12R,16R,20R)-4,8,12,16,20-pentamethyl-1,5,9,13,17-pentaoxacycloicosane-2,6,10,14,18-pentone Chemical compound C[C@@H]1CC(=O)O[C@H](C)CC(=O)O[C@H](C)CC(=O)O[C@H](C)CC(=O)O[C@H](C)CC(=O)O1 SMNJTHDCJZUGHR-KJWHEZOQSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical compound CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- GPPUPQFYDYLTIY-UHFFFAOYSA-N 2-oxooctanoic acid Chemical compound CCCCCCC(=O)C(O)=O GPPUPQFYDYLTIY-UHFFFAOYSA-N 0.000 description 1
- YBJHBAHKTGYVGT-OOZYFLPDSA-N 5-[(3as,4r,6ar)-2-oxohexahydro-1h-thieno[3,4-d]imidazol-4-yl]pentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-OOZYFLPDSA-N 0.000 description 1
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000182988 Assa Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- 241000722731 Carex Species 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 244000084296 Hernandia moerenhoutiana Species 0.000 description 1
- 235000010044 Hernandia moerenhoutiana Nutrition 0.000 description 1
- 241000948268 Meda Species 0.000 description 1
- 101100296015 Mus musculus Ovos gene Proteins 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 241000282373 Panthera pardus Species 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 101001129490 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Phosphoglycolate phosphatase 2 Proteins 0.000 description 1
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
- 240000005481 Salvia hispanica Species 0.000 description 1
- 235000001498 Salvia hispanica Nutrition 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- UELITFHSCLAHKR-UHFFFAOYSA-N acibenzolar-S-methyl Chemical compound CSC(=O)C1=CC=CC2=C1SN=N2 UELITFHSCLAHKR-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- ZKIBBIKDPHAFLN-UHFFFAOYSA-N boronium Chemical compound [H][B+]([H])([H])[H] ZKIBBIKDPHAFLN-UHFFFAOYSA-N 0.000 description 1
- 238000009933 burial Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000014167 chia Nutrition 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- -1 next Chemical compound 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000005603 pentanoic acids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/044—Pyrrole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
Definitions
- Et al. Have developed hydrogen isotopes (soG soC) and xanthone anolines that are different from natural tans. These were applied to PC containing pieces (89), and (). However, it requires a relatively modest and / or cumbersome method. In addition to these subjects, it is not recognized by soC and the anopines, 2 anopidines, and 7-pom- erase. Therefore, these are limited.
- soC soC
- 2 anopidines 2 anopidines
- 7-pom- erase 7-pom- erase. Therefore, these are limited.
- oo et al. Synthesized a base that has a form similar to the natural group, but lacks the ability to form a bond at the base (2). These sex bases were selectively recognized by pomerase, suggesting that, in replication, the geometrical complementarity of hydrogen rather than hydrogen bonds is important. Recently, it was developed by a series of sex bases, oesbe et al.
- 001 4 quaternary pomerase consists of 35 quaternary pigments, 4 pomerases and conventional pomerases (eg e ococc soas e pomerase) The method according to item 3 without aspect selected from the group.
- the deoxyribooctanoic acid to be 001 4 5 has a group of:
- the deoxyribooctanoic acid which is 001 56, has a natural group, and is described in item 4 of the non-embodiment.
- the deoxybodic pentanoic acid that is 016 7 is
- deoxycarbonyl pentacarboxylic acid having a group represented by: 5.
- Deoxybodic pentanoic acid which is 00198 is the following
- the deoxycarbonyl pentacarboxylic acid having a group represented by: 5.
- Is hydrogen is a substituted or substituted C C achi, is a substituted
- a nucleic acid that has a group represented by and forms a base that has a group represented by and forms a base.
- the base of 003 1 4 is
- Shigeo wheat which is said to have been written in the breath by Hata Ihata I3, which is made into a cedar from the groo that is composed of Le Ge.
- Aspect 3 selected from the group consisting of
- Is a photogroup An acid containing a quorum having a group represented by is transcribed as a type, reverse transcription replication is performed, and a quo having the above group is incorporated at a position of the quo having the group 2 above.
- the above-mentioned manufacturing method comprising:
- the acid containing a quorum having a group represented by is transcribed as a mold, and reverse transcription replication is performed by transferring the above-mentioned group 2 to the position of the quo having a group.
- the above-mentioned manufacturing method comprising:
- the antisense is a body or an apta.
- Quadrant having a group represented by.
- Quadrant having a group represented by.
- the quadrant 5 which is 3 or a C 2 C achi group.
- 006 007 a is 5 s C (P 75) OCT and
- Ply, 55, and • 35 quad pentanoic acid were used for C.
- the data were averaged over a set of 3 and 8 data sets.
- the replication property is further improved.
- the utilization of modified pentanoic acid reduces the loading rate compared to that of the non-converted one, the artificially incorporated reaction can be practically used by the selection. Well proceed.
- the method for the hydroxyl group of the acid at the v-position of deoxyribooctanoic acid is not particularly limited, and the following method can be used.
- 13 (5) (6) herein discloses the corresponding quads in the case of substituted ano groups.
- 47 also discloses the laws of Adequo.
- methiano, methiano, mecapto, o, and ano can be synthesized by a method known to those skilled in the art.
- Cyclic pomerases consist of groups of 35, which are pigments, 4 pomerases and conventional pomerases (e.g. e ococc soas e pomerase). To be selected.
- the group of groups in the present invention is not particularly limited, and for example, deoxybox having the following groups is used.
- the group 0104 and the deviation of 2 also show excellent selection and efficiency in replication even when used as the deviation of the template. In addition, it shows excellent selection and efficiency for transcription.
- the oxo-octanoic acid which is 0,06 or, may have a natural group.
- Deokinokudo no Aden ( ), Guan (G), and ton (C) tin () are known.
- deoxycarbonyl pentanoic acid, in which the hydroxyl group of the acid at the v-position is substituted, is effectively used as well.
- the deoxyquinodecanoic acid of 0108 may have a group of or a natural group. of ,
- the method for producing the nucleic acid is as described above.
- the deoxy quinodecanoic acid of 0109 Akira can be used as in the above-mentioned production process of Akira.
- a nucleic acid having a group represented by [0117] means that a nucleobase and a sugar group are bound by a bond. It should be noted that the acid-base is intended to include Ade, guar, ton, tin, ura, and the conductors of these groups. The type of conductor is not particularly limited, and specific examples thereof include the group represented by the above and the group represented by 2. Quo means that the amount of the quads mentioned above is not available. More preferred is one, or three. Quad or Quad, 2 Deokibo, or Gege has 2nd place 2
- the hydroxyl group of the acid at the V-position is substituted with a group selected from the group consisting of nitrogen, ano, methano, methano, mecapto group and o. Hope that. Minutes, quads, quads, quads, or the composition found in these conductors. Quo whose minutes are is minutes of, and Deokiki quo, which is minutes, is minutes of.
- the thia group is a substituent, or the 4- and / or 5-position is selected from the group consisting of a methyl group, an aryl group, a to group and a chi group. It may be replaced by more groups.
- 0120 also includes a case where s is a hydrogen atom or a case where it is a hydrogen atom or an amino group.
- s is a case where is an ano group
- s is a case of hydrogen, and s is described separately according to the following.
- 0121 can be either or. Of, for example, s.
- For C for example, express s.
- s includes s and the like.
- s and s may be collectively referred to as s.
- 0 22 is not fixed, but preferably,
- 0 (124) is more preferable than 0124.
- the group of Ming, the quad containing it, and the quo can be synthesized by the method of. Physically, for example, 3 Is 2 ano 3 to 4 quinine (compound of 1) (4) to 7 (2) 3 4 5 b 3 ii (s) quad 5 acid and 5 adon (1 or The method for synthesizing 4) is disclosed. In addition, Implementation 11 is 7 (2) 3
- the practice discloses a method for synthesizing quad 5 acids of 4 (2 2 3 b gin (s) 4 (2) 2 3 b gin ().
- Adonates can also be synthesized using methods similar to those physically disclosed in this specification and / or known to those skilled in the art.
- 0131 Ochin also called, is a member of the Vitan group. It is known that biotin binds to Avidi specific, which is a protein contained in, to form a complex. Therefore, a quad having otine as a substituent specifically binds to an avidin protein. For this reason, it can bind when avid is bound, including quads that have biotin bound, so that nucleic acids can be immobilized and separated, and nucleic acids that bind to specific molecules (such as If it becomes, for example,
- the photomolecule is capable of utilizing the photomolecule of, but preferably 5
- the large wavelength of is, and the fluorescence large wavelength of is. Also,
- the absorption wavelength of R is 578 and that of fluorescence is 578.
- the large wavelength of S is 8 and the large wavelength of fluorescence is 8.
- the large wavelength of X is, and the large wavelength of fluorescence is.
- the large wavelength of is, and the large wavelength of fluorescence is.
- the large wavelength of 5 X is 5 and the large wavelength of fluorescence is 5.
- the 6 X large wavelength is, the fluorescence large wavelength is
- a quad or a quad having a group of formula 2 having a substituted photomolecule is capable of producing a group depending on the type of fluorescent molecule.
- the photomolecule may be directly bonded through the ano group or may be bonded through the anchor.
- the type of anchor is not particularly limited, and those skilled in the art can use it. Although not limited to the above, preferably 1 and 11 below.
- 0139 R is a photogroup.
- 2 is a group, it is referred to herein as Pa or Pa depending on the context.
- P is a group, it is referred to herein as P or P, depending on the context.
- Pa, Pa, P, P, etc. may be collectively referred to as Pa.
- 040 is not fixed, but preferably 2 or less
- 6 is Pa or Pa conductor
- 72 is P or
- Pa can be introduced from its source, for example, picaboride, for example, dc 3 29 8 ec 8 757 4.
- the Pa conductor can be basically synthesized by conducting from Pa.
- a conductor that introduces a poppy in the 4th position of Pa is described in oo ed ee ⁇ 3 ⁇ 45 5 45 8 (2 3) (28).
- p2carboaldehyde (j) p2carboaldehyde (7) was synthesized.
- a nucleic acid having a group having a group of 0, a group having a group of 2 and a group having a group of 2 is formed.
- more quanta means a nucleic acid molecule bound in the 5 3 direction. Including one, two, or. , R, or. Also, is reverse-transcribed as a mold. Is also included.
- a quo having a group of formula 2 is a quo having a group of formula 2 Exist on two nuclei that form two by. Or, Quo may exist on the same book. In this case, the base may form a single structure.
- Quo having a group of 0150 and a group having a group of 2 can be incorporated into the nucleus by replication, transcription, reverse transcription reaction, or the like. Alternatively, it may be incorporated by or by chemical synthesis, as well as a quad or quad having a natural group.
- a base is formed in the process of transcription, or reverse transcription of nucleic acid.
- a quo having a group of is a part of, and a quo having a group of 2 is a part of, or vice versa.
- a quo having a group may be a part, and a quo having a group 2 may be a part.
- the outline of the stem of 0153 is shown in Fig. C.
- the effects on the production of the Ming stem are shown, for example, in 2b e, 3b and 82.
- Is hydrogen is a substituted or substituted C C achi, is a substituted
- 3 is a group selected from a substituted C 2 C3 group or a substituted or substituted C C3 group, and
- An acid containing a quorum having a group represented by is transcribed as a type, reverse transcription replication, and a quo having the above group is incorporated at a position of the quo having the above group 2.
- 0159 is also the following 2
- the acid containing a quorum having a group represented by is transcribed as a type, and the reverse transcription replication is performed, and the quo having the group 2 is incorporated at a position of the quo having the group
- 0165 is further intended to provide an acid prepared by the method described above or containing a quo having a group of formula 2.
- Nucleic acid into which the bright quan is incorporated is used as an antisense or as a vaccine or tag.
- Antisense is or that suppresses the appearance of a particular gene. It was named as a complement to the partial sequence of the target gene sequence (sense). It is used as a method to adjust the gene expression.
- Antisense or embedded with Mingo Quo contains a group Create something with different complementarity to the target compared to using only natural groups. Is a component of. Apta, a nucleic acid obtained by the o-section method and having the function of binding to a certain element of a tank
- the quasi nucleic acid (or) (eg, synthetic) of the present invention may be a part of a tank or a peptide. It is used as a light gene fragment or light source.
- natural genes with more additions of the quanta of the present invention, or combinations of these are also included.
- nucleic acid into which a quat having an explicit group is incorporated is incorporated.
- Is a phenomenon in which two (ds) are decomposed and the expression of the gene is suppressed.
- a typical example of Wataru is ds.
- Isa () belonging to 111a sets up 2 23 s s o e fe R s with about 2 ongs on the 3rd end. s is incorporated into s white matter called SC and decomposes the sequence R. It has been shown to be a phenomenon that is conserved in a wide range of species such as, (human, mouse, etc.), nematode, plant, leopard, and so on. Nucleic acids that incorporate a quat having an explicit group can be used as s in interactions or as part of undergoing degradation.
- a quad pentanoic acid having a group represented by is provided.
- 0172 is the following 2
- Is hydrogen is a substituted or substituted C C achi, is a substituted
- a quad pentanoic acid having a group represented by is provided.
- the R ano group includes a meth-, iso-, and benzoi-substituted ano group.
- 0 80 is the same as
- Example 8 was synthesized in Example 1 as a substance contained in 0181.
- Is hydrogen is a substituted or substituted C C achi, is a substituted
- 0186 R is the same as 2.
- 0187 R is the same as 2.
- 0189 a a is a system that enables singularity and copying. a represents s Pa and.
- b a is a system that allows singularity and copying.
- b shows the structures of 5 '(dP) and 5'adonic acid as for PC and ply length.
- c a is a system that allows singularity and copying. c indicates the PC width, the ply length, the ken, and the stem that functions at 7.
- 2a 2a e for stem quats and plies with s Pa. 2a is a row of plies for the entrance test.
- 2b shows the ratio of (d P) to the group by e o.
- 2c shows the ratio of (d P, Pa, G, C, and modified d P, s and) to the group by e o.
- 2d 2a e for stem quats and plies with s Pa shows the result of applying 5 between eo and 5 with dPa P and a form containing dPa in the absence of ds P.
- 2e is a type, including Pa, plus a series (ds P and P) by eo or eo "
- 3a 3a is the width and the PC width of the piece containing s Pa. 3a shows the experiment. (5e) was prepared by ply length using synthetically synthesized (9e and 8e) containing s and Pa.
- 3b 3a is the width and the width of the piece containing s Pa. 3b shows the first (cycling) and 5 and a post-cycling sample of the PCR product. Cycle your PC at (94C, O / 545C, O / 565C, 4) x 4 x
- Co containing only groups is a cyclized P C at (94. C, O. 5 45. C, O. 5 72. C,).
- 3c 3a is the width and the PC width of the piece containing s Pa. 3c shows the result of PC determination according to the procedure described for 3ab. (D) and (e) with stem (d) and (e) after dsP P (cf) or non-existent of (c) and PC's pre-PC after (s) PC or after natural-only Syc PC () Kenting in ().
- 0193c is the result of the dPa P of PC (cycl).
- the fourth group is a group corresponding to the s position of the template, and Pa is incorporated at this position in the reaction. Therefore, only at this position, the gap between G and C disappears.
- 3d 3a is the cage and PC width of the piece containing s Pa. 3c follows the procedure described for 3a b. The result of PC setting is shown. 3d is the result of the dPa P after the cycle PC.
- the fourth group is a group corresponding to the s position of the template, and Pa is incorporated at this position in the reaction. Therefore, only at this position, the gap between G and C disappears.
- 3e 3a is the width and the width of the piece containing s Pa.
- 3c shows the result of PC determination according to the procedure described for 3ab.
- 3e is the result of the dPa P after the cycle PC.
- the fourth group is a group corresponding to the s position of the template, and Pa is incorporated at this position in the reaction. Therefore, only this place, the gap between G and C disappears.
- 3 3a is the width and width of the PC containing s Pa.
- 3c shows the result of PC determination according to the procedure described for 3ab.
- 3f is the result of the dPa P quantification after PC (cycling) under the condition that s Pa does not exist in nature.
- the P in the template, which corresponds to the fourth group, is completely replaced (the fourth group).
- 39 3a is the width and the PC width of the piece containing s Pa.
- 3c shows the result of PC determination according to the procedure described for 3ab.
- 3 is the result of the ken in the presence of dPa P of PC (cycl).
- the fourth group is a group corresponding to the s position of the template, but since there is no group forming the s singularity, this drop is almost eliminated.
- 3h 3a is the width and the PC width of the piece containing s Pa.
- 3c shows the result of PC determination according to the procedure described for 3ab.
- Figure 3 is the result of the Kening in the presence of dPa P after the Cyclo PC.
- the fourth group is a group corresponding to the s position of the template, but since there is no group forming the s singularity, this drop is almost eliminated. However, the base Obstacles are also observed. The size of this overlook was naturally increased by the increase in the number of PC cycles.
- 3 3a is the width and width of the PC containing s Pa.
- 3c shows the result of PC determination according to the procedure described for 3ab.
- Figure 3 is the result of the Kening in the presence of dPa P after the Cyclo PC.
- the fourth group is a group corresponding to the s position of the template, but since there is no group forming the s singularity, this drop is almost eliminated. However, uptake of the base is also observed. The size of this overlook was naturally large due to the increase in the number of PC cycles.
- 4a 4 is at 7 mediated by s Pa.
- 4a 4b is a skit of the experiment.
- 4b 4 is at 7 mediated by s Pa. 4a 4b is a skit of the experiment.
- 4c 4 is at 7 mediated by s Pa. 4c indicates a target using Pa P, Pa P or S P () or a natural P () (s Pa Pa, or C) in the absence thereof.
- 4d 4 is at 7 mediated by s Pa.
- 4d 4 e shows the result of 2 C analysis of quaternic acid obtained from the transcript (7 e).
- 4e 4 is at 7 mediated by s Pa.
- 4d 4 e shows the result of 2 C analysis of quaternic acid obtained from the transcript (7 e).
- 5a 5 is for child 7 containing anti.
- 5a is a natural product of Pa P (3) or s P (2) Use (4 and co 4) of P (2 or 3)
- 5c 5 is for child 7 containing anti.
- 5b 5c are the
- 5d 5 is for child 7 containing anti.
- 5d is in the large intestine stem (S Roc e)
- 6 6 shows the strip rows for PC, Ken and test.
- P0 is the number of plies
- 1 is the count of hands that correspond to u products
- o is the counsel of the end of the world. The determined values are shown in the table below.
- 13 3 shows the results of die-tanking of two PCs using ply.
- 15 5 shows the result of die-tanking of 4 PCs using ply.
- 16 6 shows the result of die tokening of 5 PCs using ply.
- 17 7 shows the result of die tokening of 6 PCs using ply.
- Numeral 199 shows the result of die tokening of eight PCs using ply.
- 21 2 shows the scan of anti-containing anions in the stem from the large intestine
- 22 22 is a quad of 7 (2) 3 4 S b Shows skis for conductors. Drugs and (a) Cubis (toin) radium, 2 (tosta) on, (b) Radium, boron, Tanno, Chi (c) (d) a 2 Deoki 3 5 Tooi pentora Ku
- 23 23 is a quad conductor of 4 pibode hydrate, 4 pi pibobode hydrate, 6 ano 9 (2 deoxy
- 24a 24 is 7 (2) 3 4 5 b gin (s) Shows the spec of odds. 24a is the (z OSO d) spectrum of 6.
- 24b 24 shows the spectrum of quads of 7 (2) 3 4,5 b gin (s). 24b is a (27 z OSO d) spect (7 9) of 6.
- 24c 24 shows the spectrum of the quad of 7 (2) 3 4,5 b gin (s). 24c is a spect (OSO d) of 6.
- 24d 24 shows the spectrum of the quad of 7 (2) 3 4,5 b gin (s). 24d is O Spect (OSO d).
- 24e 24 shows the spectrum of the quad of 7 (2) 3 4,5 b gin (s). 24e is the C (75 z S d) spectrum of 6.
- 24 24 shows the spectrum of quads of 7 (2) 3 4,5 b gin (s). 24f is a 2 COS spectrum of 6.
- 249 24 shows the spectrum of quads of 7 (2) 3 4,5 b gin (s). 24 is a 2 OS spectrum of 6.
- 24h 24 has a spectrum of 7 (2) 3 4,5 b gin (s) quads. 24 is a 6 2 SQC spectrum.
- 24 24 indicates the spectrum of the quad of 7 (2) 3 445 b gin (s). 24 is a 2 C spectrum of 6.
- 24 24 shows the spectrum of the quad of 7 (2 3 4 5 b gin (s. 24 shows the 2 C spectrum of 6 ( ).
- 24 24 shows the spectrum of the quad of 7 (2) 3 4 S b gin (5). 241 is a 2 COS spectrum.
- 24m 24 shows the spectrum of the quad of 7 (2) 3 4,5 b gin (s). 24 is the 2 OS spectrum of.
- 24n 24 indicates the spectrum of the quad of 7 (2) 3 4,5 b gin (s). 24 is the 2 SC spectrum.
- 24 24 shows the spectrum of quads of 7 (2) 3 4,5 b gin (s). 24 is a 2 C spectrum.
- 24p 24 shows the spectrum of the quad of 7 (2) 3 4,5 b gin (s). 24 is the 2 C spectrum ().
- 25a 25 indicates the spectrum of quads of Phi Phi 2 borahdede 4 pipi 2 25a is the (3 z S d) spectrum of 7.
- 25b 25 is Phibobodehi 4 Phi Phi 2
- 25c 25 indicates the spectrum of the quads of Phi Phi 2 borahdede 4 Phi Phi 2 borah. 25c is a 2 COS spect of 7. 25d 25 indicates the spectrum of the quads of Phi Phi 2 Cabo Dehide 4 Phi Phi 2 Cabo Dehide. 25d is a 7 2 SQC spectrum.
- 25e 25 indicates the R-spectrum of the quad of Phi Phi 2 bordehide 4 pi Phi 2 cmergedehi. 25e, 7 of 2
- 259 25 shows the R-spectrum of the quads of Phi Phi 2 bordehide 4 pi Phi 2 cabohide. 25 is the (3 z S d) spectrum of 8.
- 25h 25 is Pabo 2 Phi Phi 2 Phi Phi 2
- 25 25 indicates the R-spectrum of the quads of Phi Phi 2 Cabo Dehydr 4 Phi Phi 2 Cabo Dehydr. 25 is a 2 COS spect of compound 8.
- 25 25 indicates the R-spectrum of the quads of Phi Phi 2 Cabo Dehydr 4 Phi Phi 2 Cabo Dehydr. 25 is the 2 O S spectrum of compound 8.
- 25k 25 indicates the R-spectrum of the quad of Phi Phi 2 bordehydr 4 pi Phi 2 bordehyde. 25 is a 2 SQC spectrum of 8.
- 25 25 indicates the R-spectrum of the quads of Phi Phi 2 Cabo Dehydr 4 Phi Phi 2 Cabo Dehydr.
- the 251 is the 2 C spectrum of compound 8.
- 25m 25 is Phi Phi 2 Shows the spect's spect spectrum. 25 is the O-spect (OSO d) of 7.
- 25n 25 indicates the R-spectrum of the quad of Phi 2 Cabo Dehydr 4 Puphi 2 Cabo Dehydr. 25 is the O-spect (OSO d) of 8.
- 27 27 is the S-spectrum of deoquinic acid.
- 28a 28a is the (27 z O) spectrum of deoquine 5 Y adonate.
- 28b 28b is the (g z O) spectrum of deoquine 5 adonate.
- 29a 29a is 7 (2) 3 (2 deoki j
- 29b 29b is 7 (2) 3 (2 deoki j
- 30b 3b shows the (27 z O) spectrum of (j) pi 2 carbode 5 (9).
- 30c 3c is the (27 z O spectrum of 4 Puphi (j) 2 cabohide 5 (2. 31a 3 a is 7 (2) 3 (j) 3. 31
- 31b 3 b shows the P (g z O) spectrum of (j) p 2 carbode 5 (9). 31c 3 c is 4 pp (j) pi 2
- 33 33 indicates a skid for a quad conductor of 7 (2) 34 S b. Medicine and (a)
- 34 34 shows the skid of a 2-topi () quad conductor. Medicine and (a) a 2 Deoki 3 5 Tooi
- 35 35 is 4 (2) b.
- 36 36 is (j) 4 (e.
- 38a 38 shows the R-spectrum of (j) 4 (quad) puppies 2 cadhide (24).
- 38a is the (3 z SO d6) spectrum of 24.
- 38b 38 shows the spectrum of (j) 4 (quad) puppies 2 cannodes (24.
- 38b shows 2 13
- 38c 38 shows the R-spectrum of (j) 4 (quad) puppies 2 cadhide (24). 38c is a 24 COS spectacle of 24.
- 38d 38 shows the R-spectrum of (j) 4 (quad) puppies 2 cadhide (24). 38d has 24 2 OS specs.
- 38e 38 shows the R-spectrum of (j) 4 (quad) puppies 2 cadhide (24). 38e is a 24 2 QC spectrum.
- 38 38 shows the R-spectrum of (j) 4 (quad) puppies 2 cadhide (24). 38f is the 2 C spectrum of 24.
- 389 38 shows the R-spectrum of (j) 4 (quad) puppies 2 cadhide (24). 38 is the 2 C-spectrum () of 24.
- Phi 2 Kadehid 5 Tosto (28) is shown by ionic color.
- 43a 43 indicates the spectrum of (j) 4 (Ochinaduppi) Pi 2 cadhide 5 toss (28). 43a has 28 (3 z O) spects
- 43b 43 indicates the spectrum of (j) 4 (Ochinaduppi) pi2cadehide5host (28). 43b is a 28 2 COS spect.
- 44a 44a shows the formation of biotinylated Pa P (o Pa P 28).
- 44b 44b shows the transcription and analysis of R-biotin by 7 using s Pa.
- 44c 44c is the true result of the biotin experiment of R-child with 7 using s Pa. 4 is .
- the model obtained by the computer, 52 is the result when using the PC width type.
- 44d 44d is a true indicator of the effect of biotin analysis.
- the biotin-streptavidin complex was separated from the 7-quadruplicate gel, and the () of the complex was determined from time to time.
- 44e 44e is the result of the analysis of 52 e containing o Pa or in the 59th position 32
- 45 45 indicates a skid of a 2-topic 4-quad conductor.
- 48 48 shows the entry scheme in (55 e), and the result, of P bound with an element, which is produced by using cement.
- 49 49 shows the entry scheme and its consequences in the (7 e) of Pa bound to a fluorophore using a 7 R polymerase.
- the conductor was manufactured in 8 columns (Scoa RPP 25 X4 6coecooes).
- 7 (2) 3 4 5 b described in 22. Physically, 7 (2) 3 445 b gin (4) is 2 ano 3 to 4 gin (compound (
- the 2022 quad pentanoic acid was synthesized according to the method disclosed in the prior art document (4345). 5 For adonic acid, the standard method (43) was modified. 9 2 marked quads. 2 4 3 2 It was turned on by Benzos 4. The quadruple conductors are
- the dried quad (o, compound 9 or 3) was dried with. It was dissolved in gin (OOu) xanthane (34. To this was added 2 4 3 2 benzoso 4 ondioxane (O 2, .o), followed by .5 bis (tothian).
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020087016493A KR101404374B1 (ko) | 2005-12-09 | 2006-12-07 | 핵산의 복제방법 및 신규한 인공 염기쌍 |
CN2006800525963A CN101365791B (zh) | 2005-12-09 | 2006-12-07 | 核酸的复制方法及新型人工碱基对 |
US12/096,517 US8030478B2 (en) | 2005-12-09 | 2006-12-07 | Method for nucleic acid replication and novel artificial base pairs |
EP06834239A EP1970445B1 (en) | 2005-12-09 | 2006-12-07 | Method for nucleic acid replication and novel artificial base pairs |
AU2006323745A AU2006323745B2 (en) | 2005-12-09 | 2006-12-07 | Method for replicating nucleic acids and novel unnatural base pairs |
JP2007549184A JP5146957B2 (ja) | 2005-12-09 | 2006-12-07 | 核酸の複製の方法及び新規人工塩基対 |
CA002642657A CA2642657A1 (en) | 2005-12-09 | 2006-12-07 | Method for replicating nucleic acids and novel unnatural base pairs |
HK09101422.7A HK1121491A1 (en) | 2005-12-09 | 2009-02-16 | Method for nucleic acid replication and novel artificial base pairs |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-356883 | 2005-12-09 | ||
JP2005356883 | 2005-12-09 | ||
JP2006189806 | 2006-07-10 | ||
JP2006-189806 | 2006-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007066737A1 true WO2007066737A1 (ja) | 2007-06-14 |
Family
ID=38122882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/324484 WO2007066737A1 (ja) | 2005-12-09 | 2006-12-07 | 核酸の複製の方法及び新規人工塩基対 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8030478B2 (ja) |
EP (1) | EP1970445B1 (ja) |
JP (1) | JP5146957B2 (ja) |
KR (1) | KR101404374B1 (ja) |
CN (1) | CN101365791B (ja) |
AU (1) | AU2006323745B2 (ja) |
CA (1) | CA2642657A1 (ja) |
HK (1) | HK1121491A1 (ja) |
WO (1) | WO2007066737A1 (ja) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009099073A1 (ja) * | 2008-02-07 | 2009-08-13 | The University Of Tokyo | 非天然塩基を含む改変tRNA及びその用途 |
WO2009123216A1 (ja) | 2008-03-31 | 2009-10-08 | 独立行政法人理化学研究所 | 高選択・高効率でpcr増幅が可能な新規dna |
WO2011043385A1 (ja) | 2009-10-06 | 2011-04-14 | 独立行政法人理化学研究所 | 特異な塩基対を形成する人工塩基対 |
WO2013073602A1 (ja) * | 2011-11-18 | 2013-05-23 | 独立行政法人理化学研究所 | 標的タンパク質に結合する核酸断片 |
US10513706B2 (en) | 2014-04-09 | 2019-12-24 | The Scripps Research Institute | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters |
US10610571B2 (en) | 2017-08-03 | 2020-04-07 | Synthorx, Inc. | Cytokine conjugates for the treatment of proliferative and infectious diseases |
US10626138B2 (en) | 2013-08-08 | 2020-04-21 | The Scripps Research Institute National Institutes Of Health (Nih), U.S. Dept Of Health And Human Services (Dhhs) | Method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides |
US10696719B2 (en) | 2016-06-24 | 2020-06-30 | The Scripps Research Institute | Nucleoside triphosphate transporter and uses thereof |
JP2021518127A (ja) * | 2018-03-21 | 2021-08-02 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 高熱安定性を持つ修飾ヌクレオシドホスフェート |
US11077195B2 (en) | 2019-02-06 | 2021-08-03 | Synthorx, Inc. | IL-2 conjugates and methods of use thereof |
WO2022131350A1 (ja) * | 2020-12-18 | 2022-06-23 | タグシクス・バイオ株式会社 | Dnaアプタマーのスクリーニングに使用可能な新規人工塩基を有するデオキシリボヌクレオシド、デオキシリボヌクレオチド、およびこれを含有する核酸 |
US11761007B2 (en) | 2015-12-18 | 2023-09-19 | The Scripps Research Institute | Production of unnatural nucleotides using a CRISPR/Cas9 system |
US11834689B2 (en) | 2017-07-11 | 2023-12-05 | The Scripps Research Institute | Incorporation of unnatural nucleotides and methods thereof |
US11879145B2 (en) | 2019-06-14 | 2024-01-23 | The Scripps Research Institute | Reagents and methods for replication, transcription, and translation in semi-synthetic organisms |
US11919934B2 (en) | 2018-02-26 | 2024-03-05 | Synthorx, Inc. | IL-15 conjugates and uses thereof |
WO2024111671A1 (ja) * | 2022-11-25 | 2024-05-30 | ゼノリス プライベート リミテッド | 核酸アプタマー |
US12173291B2 (en) | 2017-12-29 | 2024-12-24 | The Scripps Research Institute | Unnatural base pair compositions and methods of use |
US12234271B2 (en) | 2019-09-10 | 2025-02-25 | Synthorx, Inc. | Il-2 conjugates and methods of use to treat autoimmune diseases |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5649018B2 (ja) | 2005-08-04 | 2015-01-07 | タグシクス・バイオ株式会社 | 新規人工塩基対及びその利用 |
AU2016346270A1 (en) * | 2015-10-30 | 2018-05-24 | Tagcyx Biotechnologies | DNA aptamer capable of bonding to vWF |
WO2017205336A1 (en) * | 2016-05-23 | 2017-11-30 | The Trustees Of Columbia University In The City Of New York | Nucleotide derivatives and methods of use thereof |
WO2020159435A1 (en) * | 2019-01-31 | 2020-08-06 | Agency For Science, Technology And Research | Method of sequencing nucleic acid with unnatural base pairs |
CN111214484B (zh) * | 2020-01-21 | 2021-04-06 | 北京工商大学 | 一种共轭聚合物和聚集诱导发光小分子共掺的纳米粒子及其制备方法和应用 |
KR20220125170A (ko) | 2021-03-04 | 2022-09-14 | 전북대학교산학협력단 | 인공 염기 화합물, 이를 포함하는 핵산 및 이의 용도, 및 핵산 제조 방법 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1152009B2 (en) * | 1999-02-12 | 2017-09-06 | Daiichi Sankyo Company, Limited | Novel nucleosides and oligonucleotide analogues |
DE60045238D1 (de) | 1999-07-15 | 2010-12-30 | Japan Science & Tech Agency | Nukleinsäurebasenpaar |
JP4464272B2 (ja) | 2002-07-17 | 2010-05-19 | 独立行政法人科学技術振興機構 | 新規な非天然型塩基を有するヌクレオシド又はヌクレオチド及びその利用 |
WO2005026187A1 (ja) | 2003-09-10 | 2005-03-24 | Riken | 非天然型塩基を有するヌクレオシド又はヌクレオチド及びその利用 |
JP5649018B2 (ja) | 2005-08-04 | 2015-01-07 | タグシクス・バイオ株式会社 | 新規人工塩基対及びその利用 |
-
2006
- 2006-12-07 CN CN2006800525963A patent/CN101365791B/zh not_active Expired - Fee Related
- 2006-12-07 CA CA002642657A patent/CA2642657A1/en not_active Abandoned
- 2006-12-07 KR KR1020087016493A patent/KR101404374B1/ko active Active
- 2006-12-07 AU AU2006323745A patent/AU2006323745B2/en not_active Ceased
- 2006-12-07 JP JP2007549184A patent/JP5146957B2/ja active Active
- 2006-12-07 WO PCT/JP2006/324484 patent/WO2007066737A1/ja active Application Filing
- 2006-12-07 US US12/096,517 patent/US8030478B2/en active Active
- 2006-12-07 EP EP06834239A patent/EP1970445B1/en active Active
-
2009
- 2009-02-16 HK HK09101422.7A patent/HK1121491A1/xx unknown
Non-Patent Citations (9)
Title |
---|
HIARO I. ET AL.: "Idenshi ni Aratana Moji o Kumikomu -Jinkoteki na Sosuisei Enkitai no Kaihatsu-", BIONICS, vol. 3, no. 12, 1 December 2006 (2006-12-01), pages 68 - 71, XP003014228 * |
HIRAO I. ET AL.: "An unnatural hydrophobic base pair system: site-specific inCorp. of nucleotide analogs into DNA and RNA", NAT. METHODS, vol. 3, no. 9, September 2006 (2006-09-01), pages 729 - 735, XP003014227 * |
HIRAO I. ET AL.: "III Shinki Idenshi to Tanpakushitsu o Sosei suru Shinki Idenshi no Jinko Sosei", PROTEIN, NUCLEIC ACID AND ENZYME, vol. 48, no. 11, 2003, pages 1496 - 1502, XP003014225 * |
HIRAO I. ET AL.: "Non-hydrogen-bonded base pairs for specific transcription", NUCLEIC ACIDS SYMP. SER., no. 49, September 2005 (2005-09-01), pages 33 - 34, XP003008209 * |
HIRAO I.: "Seimei o Tsukuru Ichi Seimei System no Rikai ni Nozomu Kagaku Idenshi Joho no Kakucho o Mezashita Jinko Enki Tai no Sekkei Kaihatsu", CHEMISTRY & CHEMICAL INDUSTRY, vol. 59, no. 8, 1 August 2006 (2006-08-01), pages 848 - 851, XP003014229 * |
LECONTE A.M. ET AL.: "Amplify this! DNA and RNA get a third base pair", NAT. METHODS, vol. 3, no. 9, September 2006 (2006-09-01), pages 667 - 668, XP003014226 * |
MITSUI T. ET AL.: "An unnatural hydrophobic base pair with shape complementarity between pyrrole-2-carbaldehyde and 9-methylimidazo(4,5)-pyridine", J. AM. CHEM. SOC., vol. 125, no. 18, 2003, pages 5298 - 5307, XP003008207 * |
See also references of EP1970445A4 * |
STUMBER M. ET AL.: "Synthesis, characterization and application of two nucleoside triphosphate analogues, GTPgammaNH2 and GTPgammaF", EUR. J. BIOCHEM., vol. 269, no. 13, 2002, pages 3270 - 3278, XP003014224 * |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8715984B2 (en) | 2008-02-07 | 2014-05-06 | Riken | Modified tRNA containing unnatural base and use thereof |
EP2246428A1 (en) * | 2008-02-07 | 2010-11-03 | The University of Tokyo | Modified trna containing non-natural nucleotide and use thereof |
EP2246428A4 (en) * | 2008-02-07 | 2011-04-13 | Univ Tokyo | MODIFIED TRNA WITH NON-NATURAL NUCLEOTIDE AND USE THEREOF |
WO2009099073A1 (ja) * | 2008-02-07 | 2009-08-13 | The University Of Tokyo | 非天然塩基を含む改変tRNA及びその用途 |
JP5679147B2 (ja) * | 2008-02-07 | 2015-03-04 | 独立行政法人理化学研究所 | 非天然塩基を含む改変tRNA及びその用途 |
WO2009123216A1 (ja) | 2008-03-31 | 2009-10-08 | 独立行政法人理化学研究所 | 高選択・高効率でpcr増幅が可能な新規dna |
CN101981186A (zh) * | 2008-03-31 | 2011-02-23 | 塔古西库斯生物株式会社 | 可高选择性且高效率地进行pcr扩增的新型dna |
KR101556426B1 (ko) * | 2008-03-31 | 2015-10-02 | 탁시스 바이오 가부시키가이샤 | 고선택ㆍ고효율로 pcr 증폭이 가능한 신규 dna |
US8426569B2 (en) | 2008-03-31 | 2013-04-23 | Riken | DNA capable of being amplified by PCR with high selectivity and high efficiency |
AU2009232716B2 (en) * | 2008-03-31 | 2015-02-05 | Tagcyx Biotechnologies | Novel DNA capable of being amplified by PCR with high selectivity and high efficiency |
JP5424414B2 (ja) * | 2008-03-31 | 2014-02-26 | 独立行政法人理化学研究所 | 高選択・高効率でpcr増幅が可能な新規dna |
JPWO2011043385A1 (ja) * | 2009-10-06 | 2013-03-04 | 独立行政法人理化学研究所 | 特異な塩基対を形成する人工塩基対 |
WO2011043385A1 (ja) | 2009-10-06 | 2011-04-14 | 独立行政法人理化学研究所 | 特異な塩基対を形成する人工塩基対 |
US8895712B2 (en) | 2009-10-06 | 2014-11-25 | Riken | Artificial base pair capable of forming specific base pair |
CN102741266A (zh) * | 2009-10-06 | 2012-10-17 | 塔古西库斯生物株式会社 | 形成特异碱基对的人工碱基对 |
WO2013073602A1 (ja) * | 2011-11-18 | 2013-05-23 | 独立行政法人理化学研究所 | 標的タンパク質に結合する核酸断片 |
JPWO2013073602A1 (ja) * | 2011-11-18 | 2015-04-02 | 独立行政法人理化学研究所 | 標的タンパク質に結合する核酸断片 |
US9540650B2 (en) | 2011-11-18 | 2017-01-10 | Tagcyx Biotechnologies | Nucleic acid fragment binding to target protein |
US9873879B2 (en) | 2011-11-18 | 2018-01-23 | Tagcyx Biotechnologies | Nucleic acid fragment binding to target protein |
US10626138B2 (en) | 2013-08-08 | 2020-04-21 | The Scripps Research Institute National Institutes Of Health (Nih), U.S. Dept Of Health And Human Services (Dhhs) | Method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides |
US11634451B2 (en) | 2013-08-08 | 2023-04-25 | The Scripps Research Institute | Method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides |
US10513706B2 (en) | 2014-04-09 | 2019-12-24 | The Scripps Research Institute | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters |
US11466279B2 (en) | 2014-04-09 | 2022-10-11 | The Scripps Research Institute | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters |
US11761007B2 (en) | 2015-12-18 | 2023-09-19 | The Scripps Research Institute | Production of unnatural nucleotides using a CRISPR/Cas9 system |
US10696719B2 (en) | 2016-06-24 | 2020-06-30 | The Scripps Research Institute | Nucleoside triphosphate transporter and uses thereof |
US10696720B2 (en) | 2016-06-24 | 2020-06-30 | The Scripps Research Institute | Nucleoside triphosphate transporter and uses thereof |
US11834479B2 (en) | 2016-06-24 | 2023-12-05 | The Scripps Research Institute | Nucleoside triphosphate transporter and uses thereof |
US11834689B2 (en) | 2017-07-11 | 2023-12-05 | The Scripps Research Institute | Incorporation of unnatural nucleotides and methods thereof |
US10610571B2 (en) | 2017-08-03 | 2020-04-07 | Synthorx, Inc. | Cytokine conjugates for the treatment of proliferative and infectious diseases |
US11622993B2 (en) | 2017-08-03 | 2023-04-11 | Synthorx, Inc. | Cytokine conjugates for the treatment of autoimmune diseases |
US11701407B2 (en) | 2017-08-03 | 2023-07-18 | Synthorx, Inc. | Cytokine conjugates for the treatment of proliferative and infectious diseases |
US12173291B2 (en) | 2017-12-29 | 2024-12-24 | The Scripps Research Institute | Unnatural base pair compositions and methods of use |
US11919934B2 (en) | 2018-02-26 | 2024-03-05 | Synthorx, Inc. | IL-15 conjugates and uses thereof |
JP7342017B2 (ja) | 2018-03-21 | 2023-09-11 | エフ. ホフマン-ラ ロシュ アーゲー | 高熱安定性を持つ修飾ヌクレオシドホスフェート |
JP2021518127A (ja) * | 2018-03-21 | 2021-08-02 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 高熱安定性を持つ修飾ヌクレオシドホスフェート |
US11077195B2 (en) | 2019-02-06 | 2021-08-03 | Synthorx, Inc. | IL-2 conjugates and methods of use thereof |
US11879145B2 (en) | 2019-06-14 | 2024-01-23 | The Scripps Research Institute | Reagents and methods for replication, transcription, and translation in semi-synthetic organisms |
US12234271B2 (en) | 2019-09-10 | 2025-02-25 | Synthorx, Inc. | Il-2 conjugates and methods of use to treat autoimmune diseases |
WO2022131350A1 (ja) * | 2020-12-18 | 2022-06-23 | タグシクス・バイオ株式会社 | Dnaアプタマーのスクリーニングに使用可能な新規人工塩基を有するデオキシリボヌクレオシド、デオキシリボヌクレオチド、およびこれを含有する核酸 |
WO2024111671A1 (ja) * | 2022-11-25 | 2024-05-30 | ゼノリス プライベート リミテッド | 核酸アプタマー |
Also Published As
Publication number | Publication date |
---|---|
US8030478B2 (en) | 2011-10-04 |
US20100036111A1 (en) | 2010-02-11 |
EP1970445A4 (en) | 2009-07-29 |
KR101404374B1 (ko) | 2014-06-09 |
HK1121491A1 (en) | 2009-04-24 |
AU2006323745A1 (en) | 2007-06-14 |
JPWO2007066737A1 (ja) | 2009-05-21 |
KR20080093986A (ko) | 2008-10-22 |
JP5146957B2 (ja) | 2013-02-20 |
AU2006323745B2 (en) | 2012-11-22 |
CN101365791A (zh) | 2009-02-11 |
EP1970445B1 (en) | 2012-09-26 |
EP1970445A1 (en) | 2008-09-17 |
CN101365791B (zh) | 2012-07-25 |
CA2642657A1 (en) | 2007-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007066737A1 (ja) | 核酸の複製の方法及び新規人工塩基対 | |
Xue et al. | A vitamin-C-derived DNA modification catalysed by an algal TET homologue | |
CN105505939B (zh) | 与漆沟藻毒素1和4特异性结合的高亲和力适配体及其应用 | |
CN101148666B (zh) | 一组与人乳腺癌组织高特异性和高亲和力的核酸适配子及其制备方法与应用 | |
CN106029903B (zh) | 用于鉴定基因的等位基因的方法和探针 | |
Klingler et al. | DNA aptamers against the DUX4 protein reveal novel therapeutic implications for FSHD | |
CN106834515A (zh) | 一种检测met基因14外显子突变的探针库、检测方法和试剂盒 | |
CN107760686B (zh) | Dkk-1蛋白的核酸适配体及其应用 | |
CN112779260B (zh) | 黄素单核苷酸的核酸适配体、其筛选方法及应用 | |
Yin et al. | Ginseng omics for ginsenoside biosynthesis | |
CN107064515A (zh) | 一种基于点击化学的铜离子检测方法及检测试剂盒 | |
CN103627701B (zh) | 特异性靶向胃癌细胞的适配子的筛选及筛选得到的适配子 | |
CN117487813B (zh) | 特异性识别阿奇霉素的单链dna适配体序列及其应用 | |
WO2016119448A2 (zh) | 不同种属微生物间种类和丰度比较的人工外源性参照分子 | |
CN116102450B (zh) | 一种与Smurf1结合的小分子配体及其应用 | |
US20230041228A1 (en) | Small Molecule Inhibition of Micro-RNA-210 Reprograms an Oncogenic Hypoxic Circuit | |
Duan et al. | Proteome evaluation of homolog abundance patterns in Arachis hypogaea cv. Tifrunner | |
CN110408620B (zh) | 一种核酸适配子、其获得方法、其衍生物及其应用 | |
US20140024540A1 (en) | Ligand identification | |
CN114621958A (zh) | 特异性识别atp的单链dna适配体序列及其应用 | |
CN115058429A (zh) | 靶标为碱性磷酸酶异源二聚体的核酸适体及其衍生物和应用 | |
Heel et al. | Resolving the intricate binding of neomycin B to multiple binding motifs of a neomycin-sensing riboswitch aptamer by native top-down mass spectrometry and NMR spectroscopy | |
CN108342488B (zh) | 一种用于检测胃癌的试剂盒 | |
CN109439655A (zh) | 适用于超微量细胞核酸提取的试剂盒及方法 | |
WO2020264560A1 (en) | Target validation, binding site identification, and profiling of rna targets |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007549184 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087016493 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006323745 Country of ref document: AU Ref document number: 3527/CHENP/2008 Country of ref document: IN Ref document number: 2006834239 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006323745 Country of ref document: AU Date of ref document: 20061207 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680052596.3 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2642657 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12096517 Country of ref document: US |